Patients who suffer from CVD and develop CHF adversely affect prognosis [9,62]. In HF patients with reduced ejection fraction, the addition of angiotensin-converting enzyme (ACE) inhibitors to traditional treatment aids in the reduction of CHF decompensation incidences and HF-associated hospitalization cases. The gene discussed is ACE; the disease is congestive heart failure.